Geoffrey von Maltzahn

Co-Founder and Chief Innovation Officer, Indigo

United States

Geoffrey is co-founder and Chief Innovation Officer for Indigo, as well as a General Partner at Flagship Pioneering, where he focuses on inventing technologies and starting companies to address global challenges in nutrition, environmental sustainability, and medicine. He is also a co-founder of Sana Biotechnology, Kaleido Biosciences (NASDAQ:KLDO), Seres Therapeutics (NASDAQ:MCRB), Axcella Health (NASDAQ:AXLA), and others.

Geoffrey has previously served as Chief Executive Officer of Kaleido Biosciences and Chief Technology Officer at Seres Therapeutics, where he led the build-out of their human microbiome R&D platforms and the discovery of the first clinically-validated microbiome therapeutics. He was also Chief Executive Officer of Cobalt Biosystems, which merged with Sana Biotechnology.

Geoffrey has been recognized with numerous patent grants, awards, and publications. He is an inventor on over 200 patent applications and patents, was cited by Frontiers in Bioengineering and Biotechnology as the most prolific inventor in the microbiome field, and he has co-authored more than 20 peer-reviewed publications. Geoffrey has received a number of awards and honors, including: Business Insider’s 30 Biotech Leaders Under 40, Endpoints top biopharma leaders under 40, the prestigious Lemelson-MIT Student Prize, awarded to the most innovative student at MIT, and the National Inventors Hall of Fame Graduate Student Prize. He was awarded a Ph.D. in Biomedical Engineering and Medical Physics from MIT; a M.S. in Bioengineering from the University of California, San Diego; and a S.B. in Chemical Engineering from MIT.

to Top